ANL 31.40 Increased By ▲ 0.05 (0.16%)
ASC 20.90 No Change ▼ 0.00 (0%)
ASL 24.00 Increased By ▲ 0.10 (0.42%)
BOP 8.40 Decreased By ▼ -0.01 (-0.12%)
BYCO 10.14 Increased By ▲ 0.10 (1%)
FCCL 22.32 Increased By ▲ 0.12 (0.54%)
FFBL 27.40 Decreased By ▼ -0.04 (-0.15%)
FFL 20.65 Decreased By ▼ -0.14 (-0.67%)
FNEL 8.73 Decreased By ▼ -0.12 (-1.36%)
GGGL 27.75 Increased By ▲ 0.30 (1.09%)
GGL 47.15 Increased By ▲ 0.05 (0.11%)
HUMNL 7.38 Decreased By ▼ -0.02 (-0.27%)
JSCL 22.65 Increased By ▲ 0.15 (0.67%)
KAPCO 39.60 Decreased By ▼ -0.20 (-0.5%)
KEL 3.91 Decreased By ▼ -0.01 (-0.26%)
MDTL 3.76 Increased By ▲ 0.03 (0.8%)
MLCF 44.50 Increased By ▲ 0.23 (0.52%)
NETSOL 166.00 Increased By ▲ 0.05 (0.03%)
PACE 7.79 Increased By ▲ 0.12 (1.56%)
PAEL 34.11 Increased By ▲ 0.10 (0.29%)
PIBTL 11.25 No Change ▼ 0.00 (0%)
POWER 9.27 Increased By ▲ 0.07 (0.76%)
PRL 23.80 No Change ▼ 0.00 (0%)
PTC 11.81 Increased By ▲ 0.08 (0.68%)
SILK 1.84 Increased By ▲ 0.02 (1.1%)
SNGP 50.90 Increased By ▲ 1.30 (2.62%)
TELE 15.15 Increased By ▲ 0.09 (0.6%)
TRG 167.10 Increased By ▲ 0.90 (0.54%)
UNITY 42.80 Decreased By ▼ -0.17 (-0.4%)
WTL 3.73 Decreased By ▼ -0.01 (-0.27%)
BR100 5,178 Increased By ▲ 11.38 (0.22%)
BR30 26,604 Increased By ▲ 115.53 (0.44%)
KSE100 47,755 Increased By ▲ 68.26 (0.14%)
KSE30 19,143 Increased By ▲ 13.36 (0.07%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,133
4424hr
Pakistan Cases
1,015,827
4,11924hr
7.88% positivity
Sindh
371,762
Punjab
354,312
Balochistan
29,861
Islamabad
86,226
KPK
142,400

ZURICH: Roche's first-half net profit rose 2% to 8.22 billion Swiss francs ($8.96 billion) and sales increased by 8% at constant exchange rates to a better-than expected 30.71 billion francs as the Swiss drugmaker benefited from demand for COVID-19 tests.

It maintained its full-year forecast for sales to grow at a low- to mid-single-digit rate at constant exchange rates, with core earnings per share growing about the same as sales.

"Roche expects to increase its dividend in Swiss francs further," it added.

Roche posts higher profits as Covid tests surge

Diagnostics division sales grew 51% in the first half due to high demand for COVID-19 tests and strong momentum in routine testing, Roche said, helping to compensate for a 3% decline in pharmaceuticals sales, although drug sales rose in the second quarter after a weak start to the year.

"We have achieved good results in the first half, primarily thanks to the demand for our new medicines and COVID-19 tests. The Pharma Division began to grow again in the second quarter. The base diagnostics business shows strong momentum. As expected, demand for COVID-19 tests peaked in the second quarter," Chief Executive Severin Schwan said.